Project Wolbachia: Singapore fights dengue with infertile male mosquitoes

Dengue is endemic in dense tropical Singapore, and fogging plus source reduction alone could not keep outbreaks down. The National Environment Agency spent a decade studying Wolbachia before its first field pilots in 2016.

Fight mosquitoes with mosquitoes: release wAlbB-infected male Aedes aegypti that cannot bite; wild females they mate with produce no viable offspring.

NEA breeds wAlbB male Aedes aegypti at dedicated facilities — Verily runs a second — and releases them weekly across HDB estates. Deployment grew from pilot townships in 2016 to a planned 800,000 households, half of Singapore, by 2026, with a 2025 trial using releases to slow active dengue clusters.

Study sites saw Aedes aegypti populations fall 80–90%; a multi-site field study showed 75% lower risk of catching dengue, with 45% spillover protection in adjacent areas. The 2026 NEJM cluster-randomized trial across 15 clusters and 393,236 residents measured 71–72% protective efficacy, and 24 countries joined NEA's 2024 workshop on the method.

Singapore runs one of the world's most aggressive dengue-control regimes, and still the disease kept coming back in epidemic waves. Fogging kills adult mosquitoes only where it reaches, and removing breeding sites only lasts until the next rain. In 2016 the National Environment Agency began field pilots of a different logic: instead of killing Aedes aegypti, flood it with sterile suitors.

NEA breeds male Aedes aegypti infected with the wAlbB strain of Wolbachia bacteria and releases them weekly across public housing estates. The males do not bite; when they mate with wild females, cytoplasmic incompatibility makes the eggs never hatch. Repeated releases crash the next generation. Production is industrial — NEA runs one facility, Verily Life Sciences a second, with a third planned — and the program is branded and explained as Project Wolbachia, with release schedules published for residents.

The numbers held up under trial conditions: 80–90% suppression of Aedes aegypti at release sites, 75% lower risk of acquiring dengue in the multi-site field study, and 45% spillover protection for people in adjacent areas. A cluster-randomized trial published in the New England Journal of Medicine in 2026 — 15 clusters, 393,236 residents in the intervention arm — put protective efficacy at 71–72%.

The mechanism needs no behavior change: residents do not have to do anything for cytoplasmic incompatibility to work, so the intervention cannot be undone by complacency.

Only males are released and males do not bite, which made the program acceptable to a public that would never tolerate dense chemical spraying.

Naming it Project Wolbachia and publishing where and when releases happen turned an exotic-sounding experiment into a familiar neighborhood service.

The evidence was built like a drug trial — cluster-randomized with test-negative controls — which is why the NEJM published it and other cities can adopt it with confidence.

When the pest is the problem, the pest is also the delivery vehicle — but city-scale biocontrol takes a decade of patience, industrial breeding capacity and publicly earned trust.

By 2024 NEA announced expansion to 800,000 households — 50% of Singapore — by 2026, and began testing releases as an emergency tool to slow fast-growing dengue clusters in 2025. Officials from 24 countries attended NEA's November 2024 workshop on the method. A Lancet Regional Health commentary noted that Singapore's IIT-SIT approach is one of only two tools that have empirically demonstrated simultaneous reductions in dengue risk and vector abundance, making the city-state the reference deployment for dengue-endemic cities worldwide.